Symbols / TKNO Stock $3.18 +4.95% Alpha Teknova, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NGM
TKNO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Stephen Gunstream
Exch · Country NGM · United States
Market Cap 170.48M
Enterprise Value 177.34M
Income -17.26M
Sales 40.52M
FCF (ttm) -2.40M
Book/sh 1.28
Cash/sh 0.40
Employees 158
Insider 10d —
IPO Jun 25, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.15
PEG —
P/S 4.21
P/B 2.48
P/C —
EV/EBITDA -17.50
EV/Sales 4.38
Quick Ratio 3.44
Current Ratio 4.58
Debt/Eq 41.10
LT Debt/Eq —
EPS (ttm) -0.32
EPS next Y -0.39
EPS Growth —
Revenue Growth 7.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-26
ROA -9.26%
ROE -22.83%
ROIC —
Gross Margin 33.17%
Oper. Margin -41.16%
Profit Margin -42.59%
Shs Outstand 53.61M
Shs Float 10.33M
Insider Own 9.32%
Instit Own 83.43%
Short Float 12.19%
Short Ratio 10.14
Short Interest 1.33M
52W High 7.48
vs 52W High -57.49%
52W Low 1.91
vs 52W Low 66.49%
Beta 0.33
Impl. Vol. 0.00%
Rel Volume 0.36
Avg Volume 207.28K
Volume 74.11K
Target (mean) $9.00
Tgt Median $8.00
Tgt Low $7.00
Tgt High $12.00
# Analysts 3
Recom Buy
Prev Close $3.03
Price $3.18
Change 4.95%
About

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$3.18
Latest analyst target
3. DCF / Fair value
$-0.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.18
Low
$7.00
High
$12.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-07-10 reit Stephens & Co. Overweight → Overweight $5
2024-05-14 reit Stephens & Co. Overweight → Overweight $5
2024-03-12 down BTIG Buy → Neutral —
2023-07-12 init Keybanc — → Sector Weight —
2022-08-11 main Stephens & Co. — → Overweight $15
2022-03-16 main Stephens & Co. — → Overweight $26
2021-07-20 init Stephens & Co. — → Overweight $27
2021-07-20 init Cowen & Co. — → Outperform —
2021-07-20 init BTIG — → Buy $26
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-06 LOWELL MATTHEW Chief Financial Officer — 40,000 $2.19 $87,616
2026-03-06 GUNSTREAM STEPHEN Chief Executive Officer — 26,000 $2.15 $55,801
2025-06-27 DEMSKI MARTHA J. Director — 8,000 $5.06 $40,512
2025-06-17 DEMSKI MARTHA J. Director — 54,300 $0.00 $0
2025-06-17 ROBERTSON BRETT M Director — 54,300 $0.00 $0
2025-06-17 VOS ALEXANDER Director — 54,300 $0.00 $0
2025-06-17 VOS ALEXANDER Director — 54,300 $0.00 $0
2024-07-12 TELEGRAPH HILL PARTNERS IV, L.P. Beneficial Owner of more than 10% of a Class of Security — 12,096,773 $1.24 $14,999,999
2024-07-12 LOWELL MATTHEW Chief Financial Officer — 40,322 $1.24 $49,999
2024-07-12 GUNSTREAM STEPHEN Chief Executive Officer — 80,645 $1.24 $100,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
40.52
+7.35%
37.74
+2.89%
36.68
-11.43%
41.42
Operating Revenue
38.69
+7.54%
35.98
-1.92%
36.68
-11.43%
41.42
Cost Of Revenue
27.08
-11.26%
30.51
+15.64%
26.39
+10.21%
23.94
Reconciled Cost Of Revenue
21.89
-12.75%
25.08
+14.66%
21.88
-0.23%
21.93
Gross Profit
13.44
+85.88%
7.23
-29.77%
10.30
-41.08%
17.48
Operating Expense
30.42
-8.87%
33.38
-19.56%
41.49
-10.44%
46.33
Research And Development
2.20
-20.37%
2.76
-50.44%
5.57
-28.05%
7.74
Selling General And Administration
27.07
-8.14%
29.47
-15.27%
34.78
-7.13%
37.45
Selling And Marketing Expense
6.75
+6.87%
6.32
-32.26%
9.33
+1.96%
9.15
General And Administrative Expense
20.32
-12.23%
23.15
-9.04%
25.45
-10.06%
28.30
Other Gand A
20.32
-12.23%
23.15
-9.04%
25.45
-10.06%
28.30
Total Expenses
57.50
-10.01%
63.89
-5.88%
67.88
-3.41%
70.28
Operating Income
-16.98
+35.07%
-26.15
+16.20%
-31.20
-8.11%
-28.86
Total Operating Income As Reported
-16.98
+35.07%
-26.15
+26.48%
-35.56
+28.39%
-49.66
EBITDA
-10.15
+48.13%
-19.57
+36.02%
-30.59
-19.04%
-25.69
Normalized EBITDA
-10.63
+45.66%
-19.57
+22.95%
-25.40
-419.15%
-4.89
Reconciled Depreciation
6.34
-3.59%
6.58
+16.22%
5.66
+78.83%
3.17
EBIT
-16.49
+36.93%
-26.15
+27.86%
-36.24
-25.60%
-28.86
Total Unusual Items
0.48
0.00
+100.00%
-5.19
+75.06%
-20.80
Total Unusual Items Excluding Goodwill
0.48
0.00
+100.00%
-5.19
+75.06%
-20.80
Special Income Charges
0.48
0.00
+100.00%
-5.19
+75.06%
-20.80
Other Special Charges
-0.48
—
0.82
—
Impairment Of Capital Assets
—
0.00
-100.00%
4.36
-79.02%
20.80
Net Income
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Pretax Income
-17.20
+35.90%
-26.83
+27.63%
-37.08
+24.93%
-49.39
Net Non Operating Interest Income Expense
-0.71
-3.35%
-0.69
+17.53%
-0.83
-491.08%
0.21
Interest Expense Non Operating
0.71
+3.35%
0.69
-17.53%
0.83
—
Net Interest Income
-0.71
-3.35%
-0.69
+17.53%
-0.83
-491.08%
0.21
Interest Expense
0.71
+3.35%
0.69
-17.53%
0.83
—
Other Income Expense
0.48
—
-5.05
+75.68%
-20.75
Other Non Operating Income Expenses
—
—
0.14
+158.18%
0.06
Tax Provision
0.06
+165.91%
-0.09
+70.47%
-0.30
+84.50%
-1.92
Tax Rate For Calcs
0.00
+6900.00%
0.00
-62.50%
0.00
-79.49%
0.00
Tax Effect Of Unusual Items
0.10
0.00
+100.00%
-0.04
+94.88%
-0.81
Net Income Including Noncontrolling Interests
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Net Income From Continuing Operation Net Minority Interest
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Net Income From Continuing And Discontinued Operation
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Net Income Continuous Operations
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Normalized Income
-17.64
+34.04%
-26.75
+15.45%
-31.63
-15.12%
-27.48
Net Income Common Stockholders
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-0.57
+50.86%
-1.16
+31.36%
-1.69
Basic EPS
—
-0.57
+50.86%
-1.16
+31.36%
-1.69
Basic Average Shares
—
46.75
+46.91%
31.82
+13.30%
28.08
Diluted Average Shares
—
46.75
+46.91%
31.82
+13.30%
28.08
Diluted NI Availto Com Stockholders
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Amortization
1.15
+0.00%
1.15
+0.00%
1.15
+0.00%
1.15
Amortization Of Intangibles Income Statement
1.15
+0.00%
1.15
+0.00%
1.15
+0.00%
1.15
Depreciation Amortization Depletion Income Statement
1.15
+0.00%
1.15
+0.00%
1.15
+0.00%
1.15
Depreciation And Amortization In Income Statement
1.15
+0.00%
1.15
+0.00%
1.15
+0.00%
1.15
Total Other Finance Cost
—
—
0.83
+491.08%
-0.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
103.58
-12.79%
118.77
-7.64%
128.59
-15.55%
152.26
Current Assets
34.51
-19.32%
42.78
-6.32%
45.66
-25.32%
61.14
Cash Cash Equivalents And Short Term Investments
21.34
-29.80%
30.40
+6.71%
28.48
-32.56%
42.24
Cash And Cash Equivalents
5.91
+59.44%
3.71
-86.98%
28.48
-32.56%
42.24
Other Short Term Investments
15.43
-42.20%
26.69
0.00
—
Receivables
4.62
+7.10%
4.31
+9.22%
3.95
-7.82%
4.28
Accounts Receivable
4.62
+7.10%
4.31
+9.22%
3.95
-7.35%
4.26
Gross Accounts Receivable
4.64
+5.60%
4.39
+10.76%
3.97
-7.35%
4.28
Allowance For Doubtful Accounts Receivable
-0.02
+72.29%
-0.08
-315.00%
-0.02
+9.09%
-0.02
Taxes Receivable
—
—
0.00
-100.00%
0.02
Inventory
7.05
+3.72%
6.80
-41.34%
11.59
-5.33%
12.25
Raw Materials
2.84
+34.73%
2.10
-29.22%
2.97
-19.47%
3.69
Work In Process
0.10
+320.83%
0.02
-48.94%
0.05
-74.73%
0.19
Finished Goods
4.12
-11.88%
4.67
-45.50%
8.57
+2.45%
8.37
Prepaid Assets
—
—
—
2.37
Other Current Assets
1.50
+18.47%
1.27
-22.46%
1.63
-31.17%
2.37
Total Non Current Assets
69.07
-9.11%
75.99
-8.36%
82.93
-8.99%
91.12
Net PPE
55.84
-9.22%
61.52
-7.95%
66.84
-6.28%
71.31
Gross PPE
73.22
-0.74%
73.76
-0.81%
74.36
-1.94%
75.83
Accumulated Depreciation
-17.37
-41.88%
-12.24
-62.65%
-7.53
-66.55%
-4.52
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
31.32
+0.94%
31.03
-0.60%
31.21
+53.84%
20.29
Construction In Progress
2.92
+11.17%
2.62
+30.94%
2.00
-91.55%
23.71
Other Properties
14.11
-10.50%
15.77
-4.28%
16.47
-16.54%
19.74
Leases
24.87
+2.14%
24.35
-1.33%
24.67
+104.03%
12.09
Goodwill And Other Intangible Assets
11.94
-8.77%
13.09
-8.06%
14.24
-18.89%
17.56
Goodwill
—
—
—
0.00
Other Intangible Assets
11.94
-8.77%
13.09
-8.06%
14.24
-18.89%
17.56
Other Non Current Assets
1.28
-7.02%
1.38
-25.38%
1.85
-17.76%
2.25
Total Liabilities Net Minority Interest
34.81
-4.31%
36.38
-5.64%
38.55
-26.40%
52.38
Current Liabilities
7.54
-32.77%
11.21
+26.32%
8.88
-18.39%
10.88
Payables And Accrued Expenses
5.66
+5.98%
5.34
-24.38%
7.06
-16.54%
8.45
Payables
1.38
+67.03%
0.82
-44.74%
1.49
-39.04%
2.45
Accounts Payable
1.38
+67.03%
0.82
-44.74%
1.49
-39.04%
2.45
Current Accrued Expenses
4.28
-5.19%
4.51
-18.91%
5.56
-7.36%
6.00
Current Debt And Capital Lease Obligation
1.88
-67.90%
5.84
+224.18%
1.80
-18.89%
2.22
Current Debt
—
4.04
—
—
Other Current Borrowings
—
4.04
—
—
Current Capital Lease Obligation
1.88
+4.22%
1.80
-0.17%
1.80
-18.89%
2.22
Current Deferred Liabilities
0.01
-80.00%
0.03
+87.50%
0.02
-91.92%
0.20
Current Deferred Revenue
0.01
-80.00%
0.03
+87.50%
0.02
-91.92%
0.20
Total Non Current Liabilities Net Minority Interest
27.27
+8.38%
25.16
-15.20%
29.68
-28.49%
41.50
Long Term Debt And Capital Lease Obligation
26.39
+8.49%
24.33
-15.10%
28.66
-28.52%
40.09
Long Term Debt
13.12
+38.97%
9.44
-28.74%
13.25
-39.70%
21.98
Long Term Capital Lease Obligation
13.27
-10.84%
14.88
-3.38%
15.40
-14.95%
18.11
Non Current Deferred Liabilities
0.88
+6.29%
0.83
-10.01%
0.92
-24.86%
1.22
Non Current Deferred Taxes Liabilities
0.88
+6.29%
0.83
-10.01%
0.92
-24.86%
1.22
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
68.78
-16.53%
82.39
-8.49%
90.04
-9.86%
99.89
Common Stock Equity
68.78
-16.53%
82.39
-8.49%
90.04
-9.86%
99.89
Capital Stock
0.00
+0.00%
0.00
0.00
0.00
Common Stock
0.00
+0.00%
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
53.56
+0.29%
53.41
+30.93%
40.79
+44.76%
28.18
Ordinary Shares Number
53.56
+0.29%
53.41
+30.93%
40.79
+44.76%
28.18
Additional Paid In Capital
204.56
+1.81%
200.92
+10.51%
181.82
+17.39%
154.89
Retained Earnings
-135.79
-14.56%
-118.53
-29.14%
-91.79
-66.87%
-55.01
Gains Losses Not Affecting Retained Earnings
—
—
—
—
Total Equity Gross Minority Interest
68.78
-16.53%
82.39
-8.49%
90.04
-9.86%
99.89
Total Capitalization
81.90
-10.82%
91.84
-11.09%
103.29
-15.24%
121.86
Working Capital
26.97
-14.54%
31.57
-14.19%
36.78
-26.82%
50.27
Invested Capital
81.90
-14.58%
95.88
-7.17%
103.29
-15.24%
121.86
Total Debt
28.27
-6.31%
30.17
-0.94%
30.46
-28.01%
42.31
Net Debt
7.21
-26.27%
9.78
—
—
Capital Lease Obligations
15.15
-9.22%
16.68
-3.04%
17.21
-15.38%
20.33
Net Tangible Assets
56.83
-17.99%
69.30
-8.57%
75.80
-7.93%
82.33
Tangible Book Value
56.83
-17.99%
69.30
-8.57%
75.80
-7.93%
82.33
Interest Payable
0.10
+73.21%
0.06
-86.31%
0.41
0.00
Non Current Accrued Expenses
0.00
-100.00%
0.01
-90.20%
0.10
-46.60%
0.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-8.65
+30.22%
-12.39
+34.14%
-18.81
+31.34%
-27.40
Cash Flow From Continuing Operating Activities
-8.65
+30.22%
-12.39
+34.14%
-18.81
+31.34%
-27.40
Net Income From Continuing Operations
-17.26
+35.47%
-26.75
+27.28%
-36.78
+22.52%
-47.47
Depreciation Amortization Depletion
6.34
-3.59%
6.58
+16.22%
5.66
+78.83%
3.17
Depreciation
—
5.40
+20.00%
4.50
+125.00%
2.00
Amortization Cash Flow
—
1.10
+0.00%
1.10
+0.00%
1.10
Depreciation And Amortization
6.34
-3.59%
6.58
+16.22%
5.66
+78.83%
3.17
Amortization Of Intangibles
—
1.10
+0.00%
1.10
+0.00%
1.10
Other Non Cash Items
-0.12
-123.47%
0.51
-20.16%
0.64
+4.61%
0.61
Stock Based Compensation
3.43
-6.46%
3.67
-11.39%
4.14
+11.48%
3.71
Provisionand Write Offof Assets
2.12
-53.51%
4.55
+1308.36%
0.32
-53.66%
0.70
Asset Impairment Charge
0.07
-47.69%
0.13
-97.04%
4.38
-78.94%
20.83
Deferred Tax
0.05
+156.52%
-0.09
+69.74%
-0.30
+84.25%
-1.93
Deferred Income Tax
0.05
+156.52%
-0.09
+69.74%
-0.30
+84.25%
-1.93
Operating Gains Losses
0.02
-91.85%
0.23
-73.55%
0.88
+170.25%
0.33
Gain Loss On Sale Of PPE
0.02
-91.85%
0.23
+308.77%
0.06
-82.52%
0.33
Change In Working Capital
-2.68
-206.87%
-0.87
-138.82%
2.25
+130.67%
-7.33
Change In Receivables
-0.37
+24.29%
-0.49
-257.32%
0.31
-79.69%
1.55
Changes In Account Receivables
-0.37
+24.29%
-0.49
-269.18%
0.29
-23.16%
0.38
Change In Inventory
-2.37
-1070.49%
0.24
-26.06%
0.33
+104.37%
-7.55
Change In Prepaid Assets
-0.57
-3050.00%
-0.02
-113.74%
0.13
+104.69%
0.06
Change In Payables And Accrued Expense
0.54
+155.24%
-0.98
-184.52%
1.16
+53.03%
0.76
Change In Accrued Expense
0.07
+118.77%
-0.39
-120.09%
1.94
+929.79%
0.19
Change In Payable
0.47
+179.12%
-0.59
+23.16%
-0.77
-235.14%
0.57
Change In Account Payable
0.47
+179.12%
-0.59
+23.16%
-0.77
-235.14%
0.57
Change In Other Working Capital
-0.01
+89.13%
-0.09
-3.37%
-0.09
-8.54%
-0.08
Change In Other Current Assets
0.10
-79.36%
0.47
+17.50%
0.40
+119.31%
-2.07
Investing Cash Flow
10.70
+139.23%
-27.27
-252.53%
-7.74
+72.51%
-28.15
Cash Flow From Continuing Investing Activities
10.70
+139.23%
-27.27
-252.53%
-7.74
+72.51%
-28.15
Net PPE Purchase And Sale
-1.15
-14.80%
-1.00
+87.08%
-7.74
+72.51%
-28.15
Purchase Of PPE
-1.15
-2.04%
-1.12
+85.82%
-7.93
+71.81%
-28.15
Sale Of PPE
0.00
-100.00%
0.12
-36.55%
0.20
0.00
Capital Expenditure
-1.15
-2.04%
-1.12
+85.82%
-7.93
+71.81%
-28.15
Net Investment Purchase And Sale
11.85
+145.09%
-26.27
0.00
0.00
Purchase Of Investment
-17.15
+43.34%
-30.27
0.00
—
Sale Of Investment
29.00
+625.00%
4.00
0.00
0.00
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
0.15
-98.99%
14.89
+16.34%
12.80
+24.66%
10.27
Cash Flow From Continuing Financing Activities
0.15
-98.99%
14.89
+16.34%
12.80
+24.66%
10.27
Net Issuance Payments Of Debt
1.11
0.00
+100.00%
-10.00
-198.67%
10.13
Issuance Of Debt
1.11
0.00
0.00
-100.00%
10.13
Repayment Of Debt
—
0.00
+100.00%
-10.00
0.00
Long Term Debt Issuance
1.11
0.00
0.00
-100.00%
10.13
Long Term Debt Payments
—
0.00
+100.00%
-10.00
0.00
Net Long Term Debt Issuance
1.11
0.00
+100.00%
-10.00
-198.67%
10.13
Net Common Stock Issuance
0.00
-100.00%
15.10
-32.88%
22.50
0.00
Proceeds From Stock Option Exercised
0.21
+28.66%
0.16
-50.00%
0.33
-25.28%
0.44
Net Other Financing Charges
-1.17
-209.52%
-0.38
-1081.25%
-0.03
+89.58%
-0.31
Changes In Cash
2.20
+108.90%
-24.78
-80.16%
-13.75
+69.63%
-45.28
Beginning Cash Position
3.71
-86.98%
28.48
-32.56%
42.24
-51.74%
87.52
End Cash Position
5.91
+59.44%
3.71
-86.98%
28.48
-32.56%
42.24
Free Cash Flow
-9.79
+27.54%
-13.52
+49.47%
-26.75
+51.85%
-55.55
Interest Paid Supplemental Data
1.46
-5.93%
1.55
-11.26%
1.75
+1631.68%
0.10
Income Tax Paid Supplemental Data
0.00
-94.87%
0.04
0.00
0.00
Amortization Of Securities
-0.61
-78.49%
-0.34
0.00
—
Common Stock Issuance
0.00
-100.00%
15.10
-32.88%
22.50
0.00
Issuance Of Capital Stock
0.00
-100.00%
15.10
-32.88%
22.50
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category